We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+9.12%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.39M
AUM Growth
-$132K
Cap. Flow
+$358M
Cap. Flow %
6,649.45%
Top 10 Hldgs %
30.62%
Holding
156
New
15
Increased
31
Reduced
31
Closed
25

Top Buys

Rank Stock Value
1
THRD
Third Harmonic Bio
THRD
+$104M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$90.6M
3
TMO icon
Thermo Fisher Scientific
TMO
+$49.7M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$47.8M
5
BLU
BELLUS Health Inc.
BLU
+$33.8M

Top Sells

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$81.3M
2
ARQT icon
Arcutis Biotherapeutics
ARQT
+$44.9M
3
ABBV icon
AbbVie
ABBV
+$28.7M
4
VTYX
Ventyx Biosciences
VTYX
+$23.6M
5
PCVX icon
Vaxcyte
PCVX
+$20.2M

Sector Composition

Rank Sector Weight
1 Healthcare 98.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HELP
101
Cybin Inc
HELP
$491M
$5.08K 0.09%
275,095
-1,860
-0.7% -$50.4K
LLY icon
102
CALL
Eli Lilly
LLY
$1.09T
$4.85K 0.09%
+15,000
New +$4.75M
HRTX icon
103
Heron Therapeutics
HRTX
$92.3M
$4.74K 0.09%
+1,123,000
New +$4.39M
SRRK icon
104
Scholar Rock
SRRK
$5.88B
$4.63K 0.09%
667,943
-408,597
-38% -$3.4M
APLT
105
DELISTED
Applied Therapeutics
APLT
$3.95K 0.07%
4,250,000
– –
CALC icon
106
CalciMedica
CALC
$11.7M
$3.92K 0.07%
297,382
– –
VIGL
107
DELISTED
Vigil Neuroscience
VIGL
$3.74K 0.07%
411,191
– –
SGEN
108
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
$3.42K 0.06%
25,000
-25,000
-50% -$4.07M
ACHL
109
DELISTED
Achilles Therapeutics
ACHL
$3.31K 0.06%
1,463,251
-121,594
-8% -$344K
AMRX icon
110
Amneal Pharmaceuticals
AMRX
$6.02B
$3.2K 0.06%
+1,583,490
New +$4.44M
DNTH icon
111
Dianthus Therapeutics
DNTH
$5.58B
$3.17K 0.06%
140,685
– –
BNR
112
Burning Rock Biotech
BNR
$94M
$3.07K 0.06%
128,282
-10,698
-8% -$345K
HARP
113
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$2.94K 0.05%
302,591
-1,360
-0.4% -$25.4K
DYN icon
114
Dyne Therapeutics
DYN
$4.11B
$2.8K 0.05%
+220,400
New +$2.53M
LENZ
115
LENZ Therapeutics
LENZ
$178M
$2.69K 0.05%
121,202
– –
TARA icon
116
Protara Therapeutics
TARA
$214M
$2.46K 0.05%
830,641
– –
AFIB
117
DELISTED
Acutus Medical Inc
AFIB
$2.33K 0.04%
2,648,386
– –
LOGC
118
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$2.31K 0.04%
8,466,783
– –
PYXS icon
119
Pyxis Oncology
PYXS
$188M
$1.67K 0.03%
+848,252
New +$2.22M
IMDX
120
Insight Molecular Diagnostics
IMDX
$143M
$1.37K 0.03%
94,138
-47,752
-34% -$827K
OMIC
121
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$1.35K 0.03%
18,023
– –
EPIX
122
DELISTED
ESSA Pharma
EPIX
$1.17K 0.02%
+640,645
New +$1.69M
BOLT icon
123
Bolt Biotherapeutics
BOLT
$7.47M
$1.14K 0.02%
+38,553
New +$1.6M
GLUE icon
124
Monte Rosa Therapeutics
GLUE
$1.83B
$960 0.02%
+117,455
New +$1.08M
PHGE icon
125
BiomX
PHGE
$1.95M
$957 0.02%
14,808
– –
3 4
5
6 7

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q3 2022 Portfolio in Review

As of Q3 2022, OrbiMed held 156 positions worth $5.39M, down 2.4% from $5.52M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

OrbiMed deployed $358M of net new capital in Q3 2022, opening 15 new positions and adding to 31 existing holdings. Its largest new stake was Third Harmonic Bio: 5,779,071 shares worth $110K.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier.

On the sell side, the largest reduction was Biohaven Pharmaceutical Holding Company Ltd., an estimated $81.3M trimmed.

  • OrbiMed's largest Q3 2022 buy was Third Harmonic Bio: 5,779,071 shares worth $110K.
  • OrbiMed added most to Sarepta Therapeutics in Q3 2022, an estimated $90.6M increase.
  • OrbiMed's biggest Q3 2022 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $81.3M.
  • OrbiMed fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2022, selling an estimated $168K.
  • OrbiMed's ten largest holdings make up 31% of its $5.39M portfolio in Q3 2022.
  • OrbiMed opened 15 new positions and closed 25 in Q3 2022.
  • OrbiMed's portfolio value fell 2.4% quarter-over-quarter to $5.39M.

Based on OrbiMed's 13F filing for Q3 2022, filed 14 Nov 2022.